canakinumab
novartis
['leukemia', 'mds', 'canakinumab']
canakinumab in lr-mds with perhaps a higher risk profile when using ipss-m and a beautiful deep single cell analysis to understand the biology behind the dynamic responses. led by dr from at #ash2022 
Leukemia Doctor ????